Kewaunee Scientific (US:KEQU)2026-03-13 15:31Sales Performance - Sales for the quarter were $69,399,000, an increase of 3.2% from $67,167,000 in the comparable period of the prior year [90]. - Domestic sales for the quarter were $50,953,000, down 2.0% from $51,976,000 in the comparable period of the prior year, while international sales increased by 21.4% to $18,446,000 from $15,191,000 [90]. - For the nine months ended January 31, 2026, sales were $210,599,000, up 28.9% from $163,324,000 in the comparable period of the prior year, driven by a 29.6% increase in domestic sales [91]. Financial Metrics - Gross profit margin for the three months ended January 31, 2026 was 26.7%, compared to 27.4% in the prior year, while the nine-month margin improved to 28.1% from 27.4% [93]. - Operating expenses for the three months ended January 31, 2026 were $15,963,000, or 23.0% of sales, down from 24.0% in the prior year [95]. - Net earnings for the three months ended January 31, 2026 were $692,000, or $0.23 per diluted share, compared to $1,354,000, or $0.45 per diluted share, in the prior year [99]. - The Company had working capital of $54,793,000 at January 31, 2026, down from $64,651,000 at April 30, 2025, with a current ratio of 2.1-to-1.0 [101]. Order Backlog - The Company's order backlog was $183.2 million at January 31, 2026, down from $221.6 million at January 31, 2025 [92]. Strategic Acquisition - The acquisition of Nu Aire for $55.0 million enhances the Company's capabilities and market presence, particularly in laboratory furnishings [86][88]. Market Outlook - The Company anticipates continued volatility in project delivery and demand, influenced by external economic factors and construction schedules [103].